UCB announces positive Phase 3 results for rozanolixizumab i

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline results from the Phase 3 MycarinG study1 evaluating rozanolixizumab,...

Related Keywords

Japan , Denmark , Massachusetts , United States , Belgium , Boston , China , Canada , Toronto , Ontario , Brussels , Bruxelles Capitale , Seanm Healey , Samantha Masterson , Natalie Jones , Antje Witte , Laurent Schots , University Health Network , Brand Communications , Twitter , Rare Disease Communications , University Of Toronto , Myasthenia Gravis Foundation Of America , European Union , Division Of Neurology , Corporate Communications , Lancet Reg Health West Pac , Myasthenia Gravis Activities , Daily Living , Professor Vera Bril , Lead Investigator , Neuromuscular Section , Chief Executive Officer , Myasthenia Gravis Foundation , Chief Medical Officer , Generalized Myasthenia Gravis , Daily Living Profile , Myasthenia Gravis , Quantitative Myasthenia Gravis , Myasthenia Gravis Composite , Myasthenia Gravis Quality , Massachusetts General Hospital , Rare Diseases , Euronext Brussels , Disease Communications , Clinical Overview , Reg Health West , Practice Myasthenia , Test Efficacy , Accessed November , Subjects With Generalized Myasthenia Gravis , Ucb ,